Moreover, in May 2023, the FDA approved the first dual SGLT-1 and SGLT-2 inhibitor, sotagliflozin, for the broad treatment of HF, based on phase 3 results from the SCORED trial and the SOLOIST-WHF trial [105, 130]. Here, SLC5A1 is linked to hydrops fetalis.